A comparative study of cefclidin and ceftazidime in bacterial pneumonia

Kohei Hara, Shigeru Kohno, Hironobu Koga, Toshiyuki Oe, Tatsuya Katsumata, Sadahiro Asai, Hideo Mashimoto, Takashi Suyama, Koichi Watanabe, Kenji Irifune, Masahito Inuyama, Isao Makino, Akizuki Morikawa, Yuu Aoshima, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Hidetoshi Shibaki, Koji Taneichi, Masashi NakamuraIsao Sakai, Kazumi Baba, Akira Suzuki, Yasuhito Honda, Kazuo Takebe, Mitsuo Masuda, Seiichi Murakami, Hideya Murabayashi, Toyokazu Tamura, Katsumi Endo, Hisashi Goto, Noriko Fujita, Masashi Tamura, Kazuki Konishi, Fumitoshi Yamauchi, Hiroshi Ishikawa, Noriyoshi Yonetani, Harukata Ito, Megumi Fujiwara, Tamotsu Takishima, Yasuo Tanno, Kaoru Shimada, Izumi Hayashi, Kazuhiro Watanabe, Jingoro Shimada, Hiroichi Tanimoto, Kazuo Obara, Hiroyuki Kobayashi, Fumio Matsumoto, Takeo Imai, Kazuichi Nishiwaki, Tadashi Tamura, Atsuhiko Sato, Keishi Hayakawa, Ryoji Tamura, Izumi Shichi, Masahiko Okano, Niichiro Akiyama, Masami Taniguchi, Shiro Imokawa, Toshihiko Takeuchi, Yoshimitsu Hayashi, Kazuhide Yamamoto, Yasuo Yamada, Masahito Kato, Hidekazu Hanaki, Takeshi Ito, Yuji Usami, Hideaki Kuroki, Joichi Kato, Kazuo Yoshitomo, Toshihisa Fujioka, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matsuura, Fumiyuki Kuze, Takuya Kurasawa, Tatsuyoshi Ikegami, Jun Nakai, Bunichi Umeda, Takekuni Iwata, Shizuhiro Nanbu, Yoshio Taguchi, Yoshihiro Yunoki, Mari Sanno, Yoshiro Mochizuki, Tetsuji Kawamura, Takashi Hirata, Naoko Hashimoto, Hideki Nishiyama, Takakazu Sugita, Sadao Horikawa, Seiki Nakatani, Kenji Bando, Yoshinori Hasegawa, Soichiro Ikeda, Fumio Miki, Kazuya Higashino, Shinsuke Tamura, Masakiyo Nakagawa, Hitoshi Yoshida, Giichi Okuno, Motoshi Tako, Norito Iwao, Takashi Sonoda, Yoshitaka Kawai, Naoki Togawa, Takayasu Yukimasa, Rinzo Soejima, Takeshi Ogura, Fumitaka Ogushi, Koji Kawaji, Seiji Yano, Hiromitsu Torimaru, Yoshiro Sawae, Koji Takaki, Kotaro Oizumi, Atsushi Shinoda, Tsuneo Ishibashi, Masahiro Takamoto, Yoshinari Kitahara, Susumu Harada, Akira Kajiki, Hozumi Yamada, Osamu Katoh, Naoko Sueoka, Masaru Nasu, Yoichiro Goto, Tom Yamasaki, Takayoshi Tashiro, Atsushi Saito, Nobuya Ogawa, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We carried out a well-controlled trial to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in bacterial pneumonia, using ceftazime (CAZ) as the reference drug. Either drug was given intravenously in a dose of 1 g twice a day for 14 days. The following results were obtained; 1) The overall clinical efficacy rate determined by attending physicians was 86.9% (53/61) for CFCL and 90.3% (56/62) for CAZ. The efficacy rates judged by the Efficacy Assessment Committee (Study Committee) were 85.7% (54/63) for CFCL and 89.1% (57/64) for CAZ. There was no statistically significant difference in efficacy between the two drugs. 2) As for bacteriological responses, the eradication rate was 100% (28/28) in patients receiving CFCL and 96.7% (27/28) in patients receiving CAZ, with no statistically significant difference between them. 3) Adverse reactions were observed by attending physicians in 10/77 (13.0%) patients treated with CFCL and in 2/75 (2.7%) patients receiving CAZ (χ2-test, p<;0.05). The incidence of adverse reactions was significantly higher for CFCL than for CAZ. The incidence of abnormal laboratory findings assessed by attending physicians was 16.4% (12/73) for CFCL and 21.1% (15/ 71) for CAZ. The Study Committee judged that adverse reactions occurred in 9/77 (11.7%) patients receiving CFCL and 2/75 (2.7%) patients receiving CAZ, with no statistically significant difference between the two drugs. In addition, the Study Committee judged that the incidence of abnormal laboratory findings was 27.4% (20/73) for CFCL and 31.0% (22/71) for CAZ, with no statistically significant difference between them. None of the symptoms or abnormal changes were severe. 4) The usefulness rate judged by attending physicians was 83.9% (52/62) for CFCL and 86.2% (56/65) for CAZ. The usefulness rate according to the Study Committee was 76.6% (49/64) for CFCL and 89.1% (57/64) for CAZ, with no significant difference between the two drugs. On the basis of these results, CFCL was concluded to be useful in the treatment of bacterial pneumonia, providing a high clinical and bacteriological response without severe adverse reactions.

Original languageEnglish
Pages (from-to)78-103
Number of pages26
JournalChemotherapy
Volume41
Issue number1
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A comparative study of cefclidin and ceftazidime in bacterial pneumonia'. Together they form a unique fingerprint.

  • Cite this

    Hara, K., Kohno, S., Koga, H., Oe, T., Katsumata, T., Asai, S., Mashimoto, H., Suyama, T., Watanabe, K., Irifune, K., Inuyama, M., Makino, I., Morikawa, A., Aoshima, Y., Saito, A., Tomizawa, M., Nakayama, I., Shibaki, H., Taneichi, K., ... Sugawara, K. (1993). A comparative study of cefclidin and ceftazidime in bacterial pneumonia. Chemotherapy, 41(1), 78-103. https://doi.org/10.11250/chemotherapy1953.41.78